BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has granted
New York, April 7
The risks of acute myeloid leukaemia (AML)—a type of blood cancer—in children with Down syndrome is stronger than expected, according to a new study.
The study led by researchers from the University of Chicago, Davis Health and San Francisco, examined medical data of more than 3.9 million children born between 1996-2016 in seven US healthcare systems or in Ontario, Canada.
It showed that 2.8 per cent of children with Down syndrome were diagnosed with leukaemia, compared to 0.05 per cent of other children.
Key Points
In patients with RR-AML, venetoclax combination therapy resulted in responses in 31% of patients and a median OS of 6.1 months.
NPM1 mutations predicted higher response rates; adverse cytogenetics and mutations in TP53, KRAS/NRAS, and SF3B1 predicted worse OS.
Key Points
The weighted expressions of 7 coding and 3 noncoding genes is strongly associated with relapse in CN-AML patients.
The 10-gene signature is independent from mutations known to associate with outcome in AML patients.
Purpose of review: Recognition of hereditary hematopoietic malignancies impacts patient management as well as health surveillance strategies for the patient and relatives who share the causative DNA variant. In this review, barriers to the diagnosis and management of patients are outlined.